Zurcher Kantonalbank (Zurich Cantonalbank) Summit Therapeutics Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $32.8 Billion
- Q3 2024
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 6,612 shares of SMMT stock, worth $145,133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,612
Previous 6,612
-0.0%
Holding current value
$145,133
Previous $144,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SMMT
# of Institutions
201Shares Held
76.4MCall Options Held
2.01MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$536 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$240 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$173 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$119 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$76.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.42B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...